Alnylam Pharmaceuticals | ALNY

Alnylam Pharmaceuticals traded at $126.30 this Monday May 16th, decreasing $0.17 or 0.13 percent since the previous trading session. Looking back, over the last four weeks, Alnylam Pharmaceuticals lost 24.52 percent. Over the last 12 months, its price fell by 6.93 percent. Looking ahead, we forecast Alnylam Pharmaceuticals to be priced at 124.79 by the end of this quarter and at 116.05 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
126.30
Daily Change
-0.13%
Yearly
-6.93%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Takeda 3,682.00 11.00 0.30% -1.55%
Acadia Pharmaceuticals 16.79 -0.06 -0.38% -22.89%
Agios Pharmaceuticals 22.16 0.04 0.18% -59.87%
Alnylam Pharmaceuticals 126.30 -0.17 -0.13% -6.93%
Amgen 243.45 0.05 0.02% -3.54%
Arrowhead Research 32.86 1.22 3.86% -54.88%
Avrobio Inc 0.82 0.02 2.07% -91.13%
BioCryst Pharmaceuticals 8.37 -0.02 -0.24% -41.79%
Bluebird Bio 3.50 -0.07 -1.87% -88.45%
BioMarin Pharmaceutical 77.34 -0.39 -0.50% 0.53%
Intercept Pharmaceuticals 17.79 -0.09 -0.50% -1.98%
Incyte Corp 74.46 -0.45 -0.59% -9.50%
Ionis Pharmaceuticals 36.28 0.20 0.55% -5.13%
Moderna Inc 135.92 -1.99 -1.44% -15.28%
Mirati Therapeutics 57.82 0.98 1.72% -63.08%
Neurocrine Biosciences 83.80 -0.32 -0.38% -11.42%
Novartis 86.78 0.96 1.12% -2.45%
PTC Therapeutics 32.19 0.55 1.74% -15.29%
Ultragenyx Pharmaceutical 53.48 2.01 3.91% -51.51%
Regeneron Pharmaceuticals 654.18 8.66 1.34% 24.91%
Regulus Therapeutics 0.20 -0.02 -7.15% -77.91%
Sangamo BioSciences 4.04 0.02 0.50% -62.90%
Sanofi 52.18 0.15 0.29% -1.06%
Sarepta Therapeutics 67.12 1.15 1.74% -10.66%
Vertex Pharmaceuticals 254.38 7.66 3.10% 17.58%
Xencor 24.12 0.17 0.69% -40.52%

Indexes Price Day Year
USND 11679 -120.33 -1.02% -12.71%

Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company's commercial products and pipeline of investigational RNAi therapeutics are focused in four Strategic Therapeutic Areas (STArs): Genetic Medicines, Cardio-Metabolic Diseases, Hepatic Infectious Diseases and CNS/Ocular Diseases. The Company's RNAi-based medicines include ONPATTRO (patisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran). The ONPATTRO (patisiran) is an intravenously administered RNAi therapeutic targeting Transthyretin Amyloidosis (TTR). The GIVLAARI (givosiran) is used to reduce induced liver aminolevulinic acid synthase 1 mRNA, to reduction of toxins associated with attacks and other disease manifestations of Acute Hepatic Porphyria (AHP). The OXLUMO (lumasiran) is an RNAi therapeutic targeting hydroxyacid oxidase 1 for the treatment of Primary Hyperoxaluria Type 1 (PH1). The Leqvio (inclisiran) is used for the treatment of adults with hypercholesterolemia.